N4 Pharma PLC (AIM:N4P) chief executive Nigel Theobald joined Proactive's Stephen Gunnion with an update on the specialist pharmaceutical company's novel silica nanoparticle delivery system for vaccines and therapeutics.
Theobald telling Proactive that the nanoparticle, Nuvec, has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
He said N4 is now working with a good manufacturing practice (GMP) supplier to produce preclinical batches of Nuvec and should be ready to go into clinic within about 18 months, so it can be clinically validated with a proven clinical model.